

Immunthrombozytopenie (ITP) – Neue Therapieoptionen

Literaturhinweise / Quellenangaben

1. Onkopedia-Leitlinie Immunthrombozytopenie Stand August 2024. <https://www.onkopedia.com/de/onkopedia/guidelines/immunthrombozytopenie-ityp/@guideline/html/index.html>, letzter Aufruf 17.01.2025.
2. Swan D, Newland A, Rodeghiero F, Thachil J. Thrombosis in immune thrombocytopenia - current status and future perspectives. *Br J Haematol.* 2021 Sep;194(5):822–834.
3. Matzdorff A, Alesci SR, Gebhart J, Holzhauer S, Hütter-Krönke ML, Kühne T, Meyer O, Ostermann H, Pabinger I, Rummel M, Sachs UJ, Stauch T, Trautmann-Grill K, Wörmann B. Expert Report on Immune Thrombocytopenia: Current Diagnostics and Treatment – Recommendations from an Expert Group from Austria, Germany, and Switzerland. *Oncol Res Treat.* 2023;46 Suppl 2:5–44.
4. Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, Sang YQ, Bi ZM, Ren CA, Zhou F, Liu GQ, Peng J, Hou M. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. *Blood.* 2016 Jan 21;127(3):296–302; quiz 370.
5. Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, Tran TN. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. *J Asthma Allergy.* 2018 Aug 29;11:193–204.
6. Tjepkema M, Amini S, Schipperus M. Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A systematic review and meta-analysis. *Crit Rev Oncol Hematol.* 2022 Mar;171:103581.
7. Swan D, Newland A, Rodeghiero F, Thachil J. Thrombosis in immune thrombocytopenia - current status and future perspectives. *Br J Haematol.* 2021 Sep;194(5):822–834. doi: 10.1111/bjh.17390. Epub 2021 Apr 6. PMID: 33822358.
8. David J. Kuter, Waleed Ghanima, Umer Khan, Mengyao Li, Jenny Shan, Ahmed Daak, Nichola Cooper; Clinical Predictors of Response to Riltaprutinib Therapy in Patients with Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study. *Blood* 2022; 140 (Supplement 1): 5559–5561.
9. Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J. Kuter, Hanny Al-Samkari, James B. Bussel, Marie Godar, Jaume Ayguasanosa, Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian C. Newland; Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV). *Blood* 2022; 140 (Supplement 1): 6–8.
10. Mahévas M, Azzaoui I, Crickx E, Canoui-Poitaine F, Gobert D, Languille L, Limal N, Guillaud C, Croisille L, Jeljeli M, Batteux F, Baloul S, Fain O, Pirenne F, Weill JC, Reynaud CA, Godeau B, Michel M. Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial. *Haematologica.* 2021 Sep 1;106(9):2449–2457.
11. Tjønnfjord E, Holme PA, Darne B, Khelif A, Waage A, Michel M, Ben Romdhan N, Ghanima W. Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - Follow-up of the RITP study. *Br J Haematol.* 2020 Nov;191(3):460–465. doi: 10.1111/bjh.16672. Epub 2020 Apr 27. PMID: 32342497.
12. Cooper N, Ghanima W, Vianelli N, Valcárcel D, Yavaşoğlu I, Melikyan A, Yañez Ruiz E, Haenig J, Lee J, Maier J, Zolkin N, Zaja F: Sustained Response off treatment in eltrombopag-treated patients with ITP who are refractory or relapsed after first-line steroids: primary analysis of the phase II TAPER trial. *EHA Library.* Cooper N. 06/11/2022; 357156; S292.

13. Yang Z, Hu L, Zhen J, Gu Y, Liu Y, Huang S, Wei Y, Zheng H, Guo X, Chen GB, Yang Y, Xiong L, Wei F, Liu S. Genetic basis of pregnancy-associated decreased platelet counts and gestational thrombocytopenia. *Blood*. 2024 Apr 11;143(15):1528–1538. doi: 10.1182/blood.2023021925
14. Rottenstreich A, Bussel JB. Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonists. *Br J Haematol*. 2023 Dec;203(5):872–885. doi: 10.1111/bjh.19161.
15. Guillet S, Loustau V, Boutin E, Souchaud-Debouverie O, Chalumeau NC, Pascal L, Gilardin L, Terriou L, Graveleau J, Comont T, Henique H, Reynaud Q, Mahévas M, Michel M, Canoui-Poitaine F, Godeau B. Immune thrombocytopenia newly diagnosed during pregnancy: Outcome for mothers and neonates and comparison with chronic immune thrombocytopenia during pregnancy. *Am J Hematol*. 2024 Oct;99(10):2032–2036. doi: 10.1002/ajh.27432.
16. Dahiphale SM, Dewani D, Agrawal M, Dahiphale JM, Jyotsna G, Saloni, Desale R. Navigating Primary Immune Thrombocytopenia During Pregnancy With Management Strategies and Considerations: A Comprehensive Review. *Cureus*. 2024 Aug 21;16(8):e67449. doi: 10.7759/cureus.67449
17. Fogerty AE, Kuter DJ. How I treat thrombocytopenia in pregnancy. *Blood*. 2024 Feb 29;143(9):747–756. doi: 10.1182/blood.2023020726
18. Bussel JB, Knightly KA. Immune thrombocytopenia (ITP) in pregnancy. *Br J Haematol* 2024 Apr;204(4):1176–1177. doi: 10.1111/bjh.19230